A detailed history of Goldman Sachs Group Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 344,672 shares of JANX stock, worth $18.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
344,672
Previous 347,171 0.72%
Holding current value
$18.7 Million
Previous $13.1 Million 10.47%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$35.12 - $64.78 $87,764 - $161,885
-2,499 Reduced 0.72%
344,672 $14.4 Million
Q1 2024

May 15, 2024

BUY
$7.93 - $49.75 $2.44 Million - $15.3 Million
307,223 Added 769.06%
347,171 $13.1 Million
Q4 2023

Feb 13, 2024

BUY
$5.85 - $11.7 $148,613 - $297,226
25,404 Added 174.67%
39,948 $428,000
Q3 2023

May 14, 2024

SELL
$9.56 - $14.0 $242,862 - $355,656
-25,404 Reduced 63.59%
14,544 $146,000
Q3 2023

Nov 14, 2023

SELL
$9.56 - $14.0 $78,153 - $114,450
-8,175 Reduced 35.98%
14,544 $146,000
Q2 2023

May 14, 2024

BUY
$11.08 - $15.92 $89,925 - $129,206
8,116 Added 55.58%
22,719 $269,000
Q2 2023

Aug 14, 2023

BUY
$11.08 - $15.92 $251,726 - $361,686
22,719 New
22,719 $269,000
Q4 2022

May 14, 2024

BUY
$11.1 - $18.26 $6,171 - $10,152
556 Added 3.96%
14,603 $192,000
Q4 2022

Feb 13, 2023

BUY
$11.1 - $18.26 $6,171 - $10,152
556 Added 3.96%
14,603 $192,000
Q3 2022

May 14, 2024

SELL
$10.82 - $16.84 $19,659 - $30,598
-1,817 Reduced 11.45%
14,047 $190,000
Q3 2022

Nov 10, 2022

SELL
$10.82 - $16.84 $19,659 - $30,598
-1,817 Reduced 11.45%
14,047 $190,000
Q2 2022

May 14, 2024

SELL
$9.52 - $15.65 $229,279 - $376,914
-24,084 Reduced 60.29%
15,864 $194,000
Q2 2022

Aug 15, 2022

SELL
$9.52 - $15.65 $19,706 - $32,395
-2,070 Reduced 11.54%
15,864 $194,000
Q1 2022

May 16, 2022

BUY
$13.24 - $20.24 $42,182 - $64,484
3,186 Added 21.6%
17,934 $257,000
Q4 2021

Feb 14, 2022

BUY
$15.44 - $27.32 $227,709 - $402,915
14,748 New
14,748 $291,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.27B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.